Bronchiectasis Therapeutic Market Outlook:
Bronchiectasis Therapeutic Market size was valued at USD 568.94 million in 2025 and is set to exceed USD 1.09 billion by 2035, registering over 6.7% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of bronchiectasis therapeutic is estimated at USD 603.25 million.
The global bronchiectasis therapeutics market is being driven by multiple growth drivers, such as advances in diagnostic imaging, insufficient disease knowledge, and increases in chronic respiratory conditions such as COPD, bronchiectasis, and non-tuberculous mycobacterial (NTM) infections. As per a report published by NLM in October 2024, there is an increase in mortality in bronchiectasis patient cohorts in some regions of the world, with mortality rates of 16% to 24.8% in 4 to 5 years of follow-up. This chronic respiratory condition with abnormal bronchial dilation needs to be treated in the future using inhaled antibiotics, bronchodilators, corticosteroids, and airway clearance devices.
Moreover, bronchiectasis management in a clinical setting aims at limiting inflammation and infections to preserve lung function and reduce the chances of exacerbations, which is also driving the bronchiectasis therapeutic market. As per a report by NLM in October 2024, data available on the prevalence of bronchiectasis are quite diverse, with prevalence reported between 50 to 1,000 cases per 100,000 individuals. Mucolytics, macrolide antibiotics, inhaled bronchodilators, and airway clearance devices such as the oscillatory positive expiratory pressure (OPEP) system are widely used for treatment. Even if the condition remains uncured, diagnostic imaging has evolved, facilitating early detection. Bronchiectasis is now a major concern in public health and medical research, in the bronchiectasis therapeutics market, due to the escalating concerns of its disease burden and its coexistence with other chronic lung diseases.
